CAC2 Childhood Cancer Community News Digest (February 21-27)

Assorted news from last week: The story of Moonshot4Kids meets the White House Moonshot:  CAC2 Member Janet Demeter (Jack’s Angels) encourages medical research investment into cures for children with cancer at the 2022 Cancer Moonshot announcement event. CAC2 Member, the National Brain Tumor Society (NBTS) launched a new research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of renowned adult and pediatric researchers to rapidly advance a new class of promising potential treatments that can target a brain tumor’s DNA damage response network. More than 60% of patients with […]

Read more

If No One Knows, No One Cares: An Urgent Message for President Biden

By CAC2 Member Janet Demeter, Jack’s Angels “This is the wake up call of #Moonshot4Kids: medical research investment into cures for children is one area where our priorities as Americans are completely upside-down.”–Janet Demeter This is the story of Moonshot4Kids meets the White House Moonshot! I visited the White House on Feb. 2, 2022 to witness President Biden’s announcement to reignite the Cancer Moonshot.  I never expected an invitation to this event.  At the end of last year, I had been involved in a White House OSTP roundtable of stakeholders in the childhood cancer community at the end of last […]

Read more

CAC2 Childhood Cancer Community News Digest (February 14-20)

Assorted news from last week: Study finds no link between Body Mass Index and thyroid cancer in teens with nodules. When acute myeloid leukemia (AML) relapses, it is more difficult to treat and outcomes are dismal. Scientists at St. Jude Children’s Research Hospital have discovered a mutation in pediatric AML that physicians can use to identify high-risk patients and better guide treatment. An elevated level of urinary 3-methoxytyramine (3MT) is tied to poor prognosis in pediatric neuroblastoma, according to research published in JCO Precision Oncology. Researchers also found that elevated 3MT was associated with 8 differentially expressed genes, providing a gene […]

Read more

CAC2 Webinar–Better Together: Survivorship Connection

In our February CAC2 All-Member webinar CAC2 invited the Survivorship Interest Group's Better Together committee to discuss their Project Incubator initiative.  Led by Mariah Forster Olson, and joined by committee members, Nick Giallourakis and Carolyn Breinich, this project would enable survivors and their parents, caregivers, and other family members, as well as nonprofit organizations and healthcare professionals, to be connected with available resources, programs, and services to assist in the lifelong journey of childhood cancer survivorship. This will be accomplished using our Better Together spreadsheet, as well as a unique, personalized approach. Read more

CAC2 Childhood Cancer Community News Digest (February 7-13)

Assorted news from last week: Dr. Brigitte Widemann appointed as the Special Advisor to NCI Director Ned Sharpless for childhood cancer. When Jace Ward joined a clinical trial for a novel therapy for DIPG, he had been fighting a deadly brainstem tumor for more than a year. He told his Doctor at Stanford, Michelle Monje, “I know that I’m going to die, and I know this therapy will one day be the thing that cures other kids. Figure it out with me… I don’t want it to be a 5-year-old who has to go first.”  This is his story and the […]

Read more

CAC2 Childhood Cancer Community News Digest (January 31-February 6)

Assorted news from last week: The White House announced the reigniting of the Cancer Moonshot on February 2.  Two prominent items related to the childhood cancer community: To speed progress against the most deadly and rare cancers, including childhood cancers — Today, we know cancer as a disease for which we lack good strategies for developing treatments against many of the more than 200 distinct types. We can invest in a robust pipeline for new treatments, and the COVID-19 pandemic response has demonstrated we can accelerate clinical trials without compromising safety and effectiveness. To support patients, caregivers, and survivors — Today, we [...] Read more

CAC2 Childhood Cancer Community News Digest (January 24-30)

Assorted news from last week: Retinoblastoma treatment outcomes have improved globally over the past four decades but large disparities persist between higher-income and lower-income countries, with some areas having major survival gaps. Targeted health-care policy making with increased health-care financing and accessibility are needed in low-income and lower-middle-income countries to improve retinoblastoma outcomes worldwide. Scientists at the Princess Máxima Center compared the effectiveness of RNA sequencing with traditional methods that allow you to specifically search the DNA and RNA for known gene changes. Using RNA sequencing, the team picked out 40% more than they found using traditional techniques. Wiley online [...] Read more

CAC2 Webinar–Why Childhood Cancer Foundations are Adopting the Venture Philanthropy Approach

In our January CAC2 All-Member webinar CAC2 invited the following panelists to speak on Venture Philanthropy: Dean Crowe - Rally Foundation For Childhood Cancer Research, Steve Giusto - Pediatric Cancer Research Foundation, Joe McDonough - The Andrew McDonough B+ Foundation and Dena Sherwood - Arms Wide Open Childhood Cancer Foundation. Venture Philanthropy is a growing trend across many important social issues. For the childhood cancer community, one case study of venture philanthropy is with Oncoheroes Biosciences. Since October 2019, 12 childhood cancer nonprofits have invested in this biotech company that is developing new therapies for children with cancer. In this webinar, [...] Read more

CAC2 Childhood Cancer Community News Digest (January 10-23)

Assorted news from the last two weeks: Adolescents and young adult cancer survivors are more likely to have psychological distress and additional annual medical expenses than adults with no history of cancer, according to a study published in Cancer. The FDA has granted both Rare Pediatric Disease Designation and Orphan Drug Designation Lantern Pharma’s drug candidate LP-184 for the treatment of pediatric patients with ATRT. Two anti-cancer antibodies have a much stronger effect against pediatric nerve-cell and bone cancers in mice than either one alone, researchers have discovered. The Spanish perspective:  The future of pediatric oncology lies in precision medicine. […]

Read more

CAC2 Childhood Cancer Community News Digest (January 3-9)

Assorted news from the last two weeks: Children with chronic health conditions, including cancer, and those with special education needs, should receive more help with online learning. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc., a clinical-stage biotechnology company advancing new therapies for childhood cancers, today announced that they have entered into licensing agreements under which Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor, and assume responsibility for their […]

Read more

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.